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Abstract The EANM Congress 2014 took place in
Gothenburg, Sweden, from 18 to 22 October under the pres-
idency of Prof. Wim Oyen, chair of the EANM Scientific
Committee. Prof. Peter Gjertsson chaired the Local
Organizing Committee, according to the standardized
EANM congress structure. The meeting was a highlight for
the multidisciplinary community that forms the heart and soul
of nuclear medicine; attendance was exceptionally high. In
total almost 5,300 participants came to Gothenburg, and 1,
397 colleagues participated via the EANM LIVE sessions
(http://eanmlive.eanm.org/index.php). Participants from all
continents were presented with an excellent programme
consisting of symposia, scientific and featured sessions,
CME sessions, and plenary lectures. These lectures were
devoted to nuclear medicine therapy, hybrid imaging and
molecular life sciences. Two tracks were included in the
main programme, clustering multi-committee involvement:
the 5th International Symposium on Targeted Radionuclide-
therapy and Dosimetry (ISTARD) and the first Molecules to
Man (M2M) track, an initiative of the EANM Committees for
Translational Molecular Imaging, Radiopharmacy and Drug
Development. The industry made a substantial contribution to
the success of the congress demonstrating the latest technolo-
gy and innovations in the field. During the closing Highlights
Lecture, a selection of the best-rated abstracts was presented
including diverse areas of nuclear medicine: physics and in-
strumentation, radiopharmacy, preclinical imaging, oncology
(with a focus on the clinical application of newly developed
tracers) and radionuclide therapy, cardiology and neurosci-
ences. This Highlights Lecture could only be a brief summary
of the large amount of data presented and discussed during the
meeting, which can be found in much greater detail in the
congress proceedings book, published as Volume 41,
Supplement 2 of the European Journal of Nuclear Medicine
and Molecular Imaging in October 2014.
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Introduction
The 27th Annual Congress of the European Association of
Nuclear Medicine (EANM) took place in Gothenburg,
Sweden on 18 – 22 October 2014 under the chairmanship of
Prof. Wim Oyen, chair of the EANM Scientific Committee,
and Prof. Peter Gjertsson, chair of the Local Organizing
Committee. The meeting provided a forum for discussion
for those working in the broad field of nuclear medicine in
Europe and the rest of the world. The programme reflected the
recent progress in this rapidly evolving field. Scientists com-
ing from 82 countries shared their knowledge and presented
and discussed new scientific results. The programme was of
excellent quality and was based on the standardized EANM
congress structure.
The overall programme included plenary sessions,
symposia, scientific sessions, featured sessions, poster
walks and normal poster sessions, CME sessions and
pre-symposia. Two tracks were included in the main
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programme, clustering multi-committee involvement: the
5th International Symposium on Targeted Radionuclide-
therapy and Dosimetry (ISTARD) and the first
Molecules to Man (M2M) track, an initiative of the
EANM Committees for Translational Molecular
Imaging, Radiopharmacy and Drug Development, the
latter to promote high-quality research through interac-
tion between basic and translational clinical scientists,
stimulating interdisciplinary scientific discussion and ed-
ucating the clinical scientists in future developments in
the field.
Original scientific work submitted comprised 1,912 accept-
ed abstracts, along with another 103 technologist ab-
stracts. This was the second highest number of abstracts
submitted to EANM congresses (topped only by the
Milan 2012 congress with 2,079 accepted scientific ab-
stracts; Fig. 1). The majority of participants came from
Europe, while 15.4 % came from Asia and 4.7 % from
America.
Dividing the abstracts by the country of origin of the first
author, the major contributing country in absolute numbers
was Italy (221), followed by Spain (151) and Turkey (137;
Fig. 2). In relative terms per million inhabitants, however, the
first place contributor was the host country Sweden (8.2),
followed by Denmark (5.5) and Slovenia (4.8; Fig. 3). Of
interest, comparing the number of EANM congress scientific
abstracts in 2014 with the number ten years earlier (average of
2003 to 2005), an increase was seen for Sweden, Denmark,
France, UK and Spain, while other countries (especially
Belgium, Finland and Germany) showed decrease in submis-
sion rates (Fig. 4). Whether this reflects less domain-specific
activity or a dispersion phenomenon through participation in
specific clinically oriented or other international specialized
imaging congresses remains to be investigated by the national
delegates. Dividing the abstracts by category (Fig. 5), the ma-
jority of were in the fields of oncology (542, 28 %), radionu-
clide therapy (270, 14 %), hybrid imaging (217, 11 %) and
radiopharmaceuticals (214, 11 %).
All abstracts were graded by expert reviewers and,
independent of the topic, the abstracts with the best
individual scores were considered for the Highlights
Lecture that focused on the following nuclear medicine
areas: physics and instrumentation, radiopharmaceuti-
cals, preclinical imaging, oncology and radionuclide
therapy, cardiology and brain imaging. For each of these
topics, we also invited six European experts (Fig. 6), to
share their opinion regarding challenges, novel develop-
ments and needs in these specific areas. Their enthusi-
astic and skilled opinions were also shown in part dur-
ing the Lecture.
Because of time restrictions, only a selection of the excel-
lent abstracts could be presented during the Highlights Lecture
(representing only 40 % of the total presentations submitted
for the Lecture). Although strongly guided by reviewer scores,
Fig. 1 Numbers of accepted
scientific abstracts submitted to
EANM congresses 2003 – 2014
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it should be noted that the final inclusion was also
based on the personal decisions of the lecturers, seeking
to stress important work and developments in the field.
We congratulate all authors who were invited to provide
slides of their excellent work for possible inclusion in
the Highlights Lecture.
Fig. 2 Numbers of scientific abstracts accepted by EANM 2014 per country in Europe
Fig. 3 Numbers of scientific abstracts accepted by EANM 2014 per country in Europe, normalized per 10 million inhabitants
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Fig. 4 Relative change (%) in number of scientific abstracts accepted by EANM for European countries over the past decade
Fig. 5 Evolution of abstracts accepted by EANM by category over the past 5 years
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Instrumentation and methods: BTowards hybrid
quantitative validation^
One of the most exciting technological developments of the
past years is the introduction of the hybrid PET/MRI scanner
that combines the high sensitivity molecular imaging with the
high time and spatial resolution of MRI. Apart from its struc-
turally superior tissue contrast and resolution,MRI also allows
complementary functional and molecular imaging. Gutte et al.
[1] used simultaneous PET/MRI with18F-FDG and 13C-pyru-
vate in a liposarcoma model, using the dynamic nuclear po-
larization technique which enables imaging of pyruvate and
its metabolites, such as lactate, thereby allowing simultaneous
combined imaging of not only glycolysis (FDG), but also
increased lactate generation, the well-known Warburg effect.
It is expected that this combined technique will allow expand-
ed noninvasive phenotyping of tumours with higher specific-
ity (Fig. 7).
There are a number of important incompletely solved tech-
nical challenges with PET/MRI, one of which is undoubtedly
the correction for attenuation when using algorithms based on
dedicated MR sequences using tissue classification. Boellaard
et al. [2] showed that for the different current PET/MRI ven-
dors these algorithms work reasonably well in patients al-
though a quantification bias can exist. Moreover, dedicated
acquisition protocols are needed for quality control and
multicentre instrumentation calibration, as severe quantitative
artefacts and underestimation of SUVs were seen when using
clinical protocols for phantom studies. Availability of time-of-
flight (TOF) within a simultaneous PET/MRI system may
provide an elegant way of estimating joint emission and trans-
mission data.
Iaguru et al. [3] reported pilot results of a TOF PET/MRI
system in oncology, showing excellent performance of the
TOF PET component and examples of improved signal-to-
noise and disease detection when compared with a similar
TOF PET/CT system (Fig. 8). As in most current comparative
studies, PET/MR is performed after PET/CT as the current
standard of care technique, which may give rise to some
timing bias, so randomized timing studies are needed to fur-
ther validate these comparisons. PET/MRI can be used for on-
the-fly motion correction. Keller et al. [4] showed that sparse-
ly sampled MR structural navigators inside a full MRI
multisequence protocol can be used, and results in improved
image quality and decreased motion blur (Fig. 9).
Another hardware development for SPECT is the availabil-
ity of dedicated solid-state cameras for cardiac imaging. In
order to realize the ultimate goal of quantitative cardiac
SPECT, one important aspect is motion correction, for which
solid-state CZT (cadmium zinc telluride) cameras can be
Fig. 6 The six nuclear domains depicted in the Highlights Lecture, with the respective experts who were consulted on trends, challenges and
developments
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sensitive, due to simultaneous multiangle acquisition.
Kennedy and Strauss [5] showed that total perfusion defects
can be erroneously large with movements that surpass 10 mm.
In such cases, selective rejection of projection data where
greatest motion induced blur, results in better image
contrast and improved perfusion defect quantification.
The penalty from lower count rates in the clinical image
was marginal because of the high sensitivity of the CZT
camera.
In general, PET and SPECT should be quantitative tech-
niques measuring biologically meaningful parameters.
Several authors have addressed the important issue of validat-
ing simplified approaches compared to full kinetic modelling
(allowing better patient comfort or animal welfare in preclin-
ical studies) without introducing significant bias and loss in
quantitative accuracy. Alves et al. [6] showed that dual time-
point quantification of among others the serotonin synthesis
marker 11C-5HT-P allows quantitatively accurate measure-
ments without invasive cannulization.
New radionuclide therapy applications can be monitored
using continuous-spectrum bremsstrahlung imaging. Hesse
et al. [7] showed that current gamma cameras are not optimal
Fig. 8 Comparison of TOF PET/CT and TOF PET/MRI for the detection of cervical lymph nodes [3]
Fig. 7 Simultaneous 18F-FDG
PET and 13C-pyruvate PET/MRI
imaging of liposarcoma in a dog
[1]
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for this goal, as even with a high-energy global purpose colli-
mator, typically only 15 % of detected events are originating
from bremsstrahlung as scatter and septal penetration is ex-
tremely high. To optimize this, they used Monte Carlo simu-
lations of a new detector with BGO (better stopping power) in
combination with a pinhole collimator to ameliorate the
signal-to-scatter ratio, resulting in a tenfold higher spectral
signal of 90Y in air across the whole energy spectrum. This
allows fabrication of a portable system for 2-min continuous
emission tomography in the catheter room during beta therapy
administration (Fig. 10). Finally, as one of the highlighted
technologist contributions, Dore et al. [8] showed that conven-
tional dose calibrators for novel radionuclide therapy applica-
tions such as 223Ra also have the desired linearity and long-
term accuracy characteristics for the more challenging physi-
cal characteristics of α emitters. They found that low back-
ground and absence of contamination traces are even more
important in this setting.
Fig. 9 Use of sparsely sampled
MR navigators as a tool for
correction of head motion in
simultaneous PET/MRI [4]
Fig. 10 Improved signal-to-noise
ratio of BGO detectors for
measuring bremsstrahlung in 90Y
radionuclide therapy monitoring
[8]
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We are moving towards quantitation and personalized nu-
clear medicine, with improvements in dosimetry, standardiza-
tion and quantification. PET/MRI and CZT SPECTare here to
stay, and show considerable promise for addressing true quan-
titative and multimodal structural plus functional evaluation.
To quote Prof. Roland Boellaard (from the movie shown dur-
ing the Lecture): BThe biggest challenge for medical imaging
in general is to collect high quality, highly standardized image
datasets in order to implement and develop, but also to vali-
date, those new technologies and those advanced data analysis
methods^.
Radiopharmaceuticals and drug development: BImprove
the success ratesB
A strongly increasing interest in positron-emitting
radiometals has been observed recently. In this context
44Sc is an interesting candidate. Hernandez et al. [9]
explored the advantageous radionuclide characteristics
of 44Sc for the development of a cyclic dimeric RGD
peptide-based tracer for in vivo PET imaging of αvβ3
integrin-associated angiogenesis processes, and using a
well-established tumour angiogenesis model showed the
feasibility of 44Sc for the development of PET tracers.
As for new ta rge t s , the g lucose -dependen t
insulinotropic polypeptide receptor (GIPR), an interest-
ing target for the imaging of neuroendocrine tumours
(NET), was presented by Gourni et al. [10]. This new
family of peptide receptors, the incretin receptor family,
may be of great importance because it may enable
in vivo peptide-based receptor targeting of NETs which
do not express somatostatin (sst) receptors, prompting
the authors to evaluate newly developed radioligands
for the in vivo targeting of GIPR-positive tumours.
The good characteristics of several of their newly de-
veloped radioligands, based on high receptor affinity,
good internalization properties and specific targeting
in vivo, support the potential of these radioligands as
PET imaging probes for a broader spectrum of NETs
(Fig. 11).
Garousi et al. [11] introduced a novel class of
scaffold-based affinity proteins, ADAPT (ABD-based d-
erived affinity protein), derived from an albumin-
binding domain (ABD). human epidermal growth factor
2-binding (HER2-binding) 111In-DOTA-(HE)3-ADAPT6
was presented. This protein had promising characteris-
tics in vitro and in vivo in a preclinical model and
showed high-contrast in vivo imaging, making it prom-
ising for further evaluation, also with short-lived
radionuclides.
Prostate-specific membrane antigen (PSMA) is definitely
one of the most promising targets for prostate cancer imaging.
In this area, there were several very interesting presentations.
Nawaz et al. [12] presented a single-chain variable fragment
(scFv) of the monoclonal antibody (mAb) J591. ACys residue
was introduced for conjugation with the bifunctional chelator
YM103 and labelling with 68Ga. The radiolabelled product
was stable in serum and showed selective and favourable
binding to PSMA-positive cells in vitro and in vivo in
mice, warranting further evaluation as a clinical agent
for imaging PSMA expression in prostate cancer.
Another presentation on PSMA-targeting ligands was
given by Chatalic et al. [13]. They developed a novel
anti-PSMA nanobody (JVZ-007), a small antibody frag-
ment possessing excellent molecular imaging properties,
high target specificity and rapid background clearance.
They evaluated the targeting properties of the radiolabelled
nanobody in tumour-bearing mice. Replacement of the his-
myc tag by the cys tag as well as coinjection with
Gelofusine significantly diminished kidney retention,
resulting in excellent tumour-to-kidney ratios, bringing the
theranostic potential of JVZ-007 in PSMA-positive prostate
cancer within reach.
Antagonists targeting gastrin-releasing peptide receptor
(GRPR) are also promising for prostate cancer imaging.
They offer good tumour retention of radioactivity and fast
washout from receptor-positive normal organs without induc-
ing any side effects. Such peptide analogues are however
well-known substrates for the protease neutral endopeptidase
(NEP) that is abundantly expressed in mammalian tissues.
Lymperis et al. [14] introduced SB3, a new DOTA-
functionalized analogue of the potent and selective GRPR
antagonist [DPhe 6,Leu-NHEt 13]BBN(6-13)], suitable for
labelling with the theranostic 111In/177Lu radionuclide pair.
They evaluated the impact of transient in vivo NEP inhibition
using the potent, competitive and reversible NEP inhibitor
phosporamidon (PA). It was found that PA treatment sup-
pressed the degradation of the radioligands, inducing remark-
able enhancement of tumour uptake in a prostate cancer
mouse model (Fig. 12). Based on the same principle,
Kaloudi et al. [15] explored the impact of PA coinjection with
the truncated gastrin analogue [111In]SG5 with very high spe-
cific activity of 111In (by HPLC purification unlabelled SG5
was removed). The combined approach impressively boosted
tumour uptake and may allow clinical application of potent
internalizing peptide receptor agonists without bioactivity
concerns. In vivo NEP inhibition appears to be a very power-
ful new tool strengthening the theranostic potential of peptide-
based radioligands, and further investigation for translation
into the clinic is warranted.
The large number of excellent abstracts during the EANM
meeting concerning new radiopharmaceuticals, based on new
vectors or novel radionuclides, is most promising. Hopes for
the future however depend on the successful introduction of
such new drugs into clinical use. We quote Prof. Hans-Jürgen
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Wester (from the movie shown during the Lecture): BTo im-
prove our success rate we need goal-oriented alignment of
academic research, including the selection of and subsequent
focus on the really promising tracers for fast and efficient
transfer and clinical assessment based on harmonized
protocols^.
Fig. 12 Phosporamidon
improves tumour uptake of SB3
[14]
Fig. 11 Evaluation of glucose-dependent insulinotropic polypeptide receptor (GIPR) ligands for neuroendocrine tumours [10]
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Preclinical imaging: BPave the translational roadB
Preclinical evaluation and imaging studies of many different
novel and promising tracers were also presented during the
meeting.
Due to its association with tumour aggressiveness and me-
tastasis, novel predictive biomarkers associated with
epithelial-to-mesenchymal transition (EMT) events in vivo
would be very helpful. Hernandez et al. [16] evaluated
CD146, an EMT inducer, as a novel in vivo target for nonin-
vasive imaging of EMT in an orthotopic glioblastoma model.
They developed a highly specific anti-CD146 mAb (YY146)
and presented noninvasive PET imaging of CD146 expression
in vivo in mice (Fig. 13), envisaging the potential of this novel
mAb for targeted cancer diagnostics and/or therapy.
Radiotracers targeting tumour-associated macrophages
(TAMs) also deserve attention. They could be valuable for
noninvasive, longitudinal visualization of macrophage infil-
tration to monitor response of drugs affecting TAMs. Terry
et al. [17] developed an imaging agent to monitor TAMs based
on the F4/80 receptor, which encodes an adhesion G protein-
coupled receptor expressed on the surface of murine macro-
phages. Binding of 111In-anti-F4/80 was specific, but in vivo,
111In-F4/80 had a short circulation time as the spleen and liver
acted as sink organs. Increasing the antibody dose to 100 μg
111In-F4/80 decreased spleen-to-blood and enhanced tumour-
to-blood uptake ratios compared to 10 μg 111In-F4/80. TAMs
could subsequently be successfully visualized by
microSPECT, as were macrophages in the spleen and liver.
Amouroux et al. [18] applied targeting of the bradykinin
B1 receptor (B1R), a G protein-coupled receptor, which is
overexpressed in a variety of cancers but not in normal tissues
making it a promising imaging marker for cancer diagnosis.
Three 68Ga-labelled B1R-targeting peptides generated specif-
ic and high-contrast images of hB1R-positive tumour xeno-
grafts in mice. P04158 and Z02090 appeared to be the most
promising analogues for imaging B1R expression with PET,
as they showed significantly higher tumour uptake and target-
to-nontarget ratios, probably due to their higher receptor
affinity.
The folate receptor is another very interesting target for
both imaging and therapy due to its overexpression in a vari-
ety of tumour types of epithelial origin. Betzel et al. [19]
presented the syntheses, biological evaluation and com-
parison of two pairs of folic acid conjugates labelled
with 18F in both the α and γ positions of the carboxylic
functionalities. The authors demonstrated that α-
conjugated and γ-conjugated folate derivatives show
different in vivo properties, while in vitro binding affin-
ity to the folate receptor is almost identical. The site of
conjugation on the glutamyl moiety in folic acid can
therefore have dramatic effects on the in vivo behaviour
of folic acid conjugates (Fig. 14)
Very well-known tumour targets are sst receptors. Receptor
antagonists have recently been shown to have higher uptake in
sst receptor-expressing tumours than sst agonists, possibly due
to the higher number of available receptor binding sites.
Nicolas et al. [20] evaluated the tumour residence time and
therapeutic index of the sst2 antagonist OPS201 compared to
the sst2 agonist DOTA-TATE in a theranostic approach in
mice. The increased tumour uptake and prolonged residence
time of 177Lu-OPS201 as well as the favourable differential
washout compared to 177Lu-DOTA-TATE improved the ther-
apeutic index of the former. The mass-dependent study con-
firmed the higher number of binding sites for the antagonists
in vivo compared to the agonist (Fig. 15).
Fig. 13 Imaging ofα-conjugated
and γ-conjugated folate acid
derivatives [19]
790 Eur J Nucl Med Mol Imaging (2015) 42:781–802
In several papers the theranostic potential of novel com-
pounds was underlined. Nuclear medicine can offer valuable
and clinically important links between imaging and therapy. A
highly ranked paper on radionuclide therapy antitumour ef-
fects was presented by Yook et al. [21], who aimed to improve
localized brachytherapy radiation treatment of locally
advanced breast cancer using locally administered EGFR-
targeted gold nanoparticles labelled with the β-emitter 177Lu
(177Lu-T-AuNPs). The authors found that the labelled parti-
cles were cytotoxic towards breast cancer cells in vitro and
slowed tumour growth in vivo. EGFR targeting increased cy-
totoxic potency in vitro, but appeared not to be required
Fig. 14 Preclinical studies with
YY-146 [16]
Fig. 15 Improved therapeutic
index of 177Lu-labelled OPS201
versus DOTA-TATE [20]
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in vivo due to local tumour retention of both targeting and
nontargeting particles following intratumoral injection.
Powerful α particle emitters are especially promising for
radionuclide therapy, and several papers were presented on
this topic. Ladjohounlou et al. [22] compared the anti-
tumour efficacy and toxicity of non-internalizing (anti-CEA)
and internalizing (anti-HER2) 212Pb-labelled mAbs during α-
radioimmunotherapy (α-RIT) of small-volume peritoneal car-
cinomatosis. They also assessed the relationship between tis-
sue absorbed doses and biological endpoints. The authors
found a strong therapeutic efficacy of 212Pb-labelled mAbs
in intraperitoneal α-RIT of small-volume tumours.
Internalizing 212Pb-labelled mAbs were more efficient, al-
though the tumour absorbed dose was lower than for non-
internalizing 212Pb-labelled mAbs, which could be explained
by the differential distribution: the distribution of the anti-
CEA radiolabelled mAb was more heterogeneous at the tu-
mour tissue level.
We hope that the promising tracers and techniques present-
ed here will find their way into the clinic, but several hurdles
will have to be overcome. The new M2M Track during the
meeting aims to bring together and train translational scientists
to improve our successes in this respect. We quote Prof. Otto
Boerman (from the movie shown during the Lecture):
BCurrently it takes too much time and money to determine
the potential of useful tracers in the clinic. The micro-dosing
guideline is a step in the right direction, but more adjustments
are needed. The new M2M Track during the EANM meeting
will improve the visibility of translational research in our field
and stimulate discussions on how to proceed^.
Cardiology and vessel disorders: BHarder, Better, Faster,
Stronger^
Several new radiotracers that are in late preclinical or early
clinical development were presented. Imaging of thromboem-
bolic disease, such as myocardial infarction, stroke, TIA and
pulmonary embolism, is of high medical importance as these
disorders are major causes of morbidity and mortality world-
wide. Currently no established whole-body imaging method is
available to systematically search for the embolic source. The
glycoprotein (GP) IIb/IIIa receptor is a key receptor required
for platelet aggregation by primarily binding fibrinogen and is
highly abundant in platelets. Specific imaging of the GPIIb/
IIIa was shown for the first time by Stephens et al. [23] in
preclinical studies in the monkey in arterial thrombi and on
damaged endothelial surface (Fig. 16). The 18F-GP1 tracer
showed very good imaging characteristics including high af-
finity (18 nM), in vivo and ex vivo selectivity, stable binding,
no influence by anticoagulation therapy and highly sensitive
and specific in vivo detection of platelet depositions.
Demeure et al. [24] reported on a novel 18F-labelled fatty
acid analogue, FCPHA, for imaging of myocardial ischaemia.
They showed the results of the phase II trial data assessing
safety, kinetics, biodistribution and optimal timing. Diagnostic
images can be very rapidly acquired even from 5 min after
injection, with no liver interference.
Also in the domain of cardiology, PET/MRI has promising
features and applications. Nappi et al. [25] performed a feasi-
bility study of simultaneous PET/MRI in Anderson-Fabry dis-
ease. This X-linked lysosomal storage disorder is associated
with severe multiorgan dysfunction and premature death
caused by renal failure, cardiomyopathy or cerebrovascular
disease. Early diagnosis and comorbidity monitoring is of
key importance to assess organ involvement. This group stud-
ied 13 patients with normal LV EF and no known cardiac
disease, and found complementary information on early dis-
ease presence from a combination of late gadolinium enhance-
ment as an expression of intermyocardial fibrosis, short inver-
sion time inversion recovery indicative of oedema, and vary-
ing patterns of FDG uptake indicative of inflammation
(Fig. 17).
Several novel studies on cardiac imaging systems and
methodology were presented. Sciagra et al. [26] used ad-
vanced pixel-wise mapping of ammonia PET in patients with
hypertrophic cardiomyopathy, in which wall thickness may be
large enough compared to the system resolution to study sub-
endocardial ischaemia. After dipyridamole stress, the internal
layer was decreased in patients with hypertrophic cardiomy-
opathy, and the difference after stress was highly significant
compared to controls, with also a higher proportion of de-
creased segments compared to the external myocardial blood
flow (MBF). This indicates that pixel-wise parametric map-
ping could be useful for identifying intramyocardial differ-
ences in MBF that are not detectable by conventional segment
schemes.
Kero et al. [27] developed an accurate semiautomatic anal-
ysis of cardiac 11C-PIB retention to allow noninvasive diag-
nosis of different forms of amyloidosis in the heart. In ten
patients with systemic amyloidosis, the cardiac amyloid load
was assessed using the fractional uptake ratio as quantitative
index. Parametric polar maps and histogram analysis allowed
fast, reproducible and straightforward interpretation (Fig. 18),
with differentiation of TTR (transthyretin) amyloidosis (with
low but increased uptake), light-chain precursor kappa amy-
loidosis (with moderately elevated uptake) and light-chain
lambda fragment amyloidosis (with very high global or re-
gional uptake).
Boemio et al. [28] investigated cardiac insulin resistance,
which at the same time represents the cause and the conse-
quence of heart failure and can affect prognosis. These authors
investigated whether insulin resistance is associated with im-
paired cardiac sympathetic innervation in a study with 95
subjects. Insulin-resistant subjects indeed showed impaired
792 Eur J Nucl Med Mol Imaging (2015) 42:781–802
heart-to-mediastinum ratios in both the early and late phase,
while the washout was not different. Both early and late ratios
were related to both fasting insulinaemia and to the HOMA-IR
(homeostasis model assessment insulin resistance) index as
calculated from fasting glucose and fasting insulin. This rela-
tionship gives mechanistic support for the theory that insulin
resistance may have an independent adverse effect on
prognosis in patients with heart failure through sympathetic
nervous system overactivity.
One advantage of recently marketed high-sensitivity dedi-
cated cardiac instrumentation, such as semiconductor cam-
eras, is the dramatic reduction in the combination of activity
and acquisition time needed. Perrin et al. [29], who advocate a
stress-first examination and perform a rest study only if




inversion time inversion recovery
Fig. 16 Characterization and
preclinical studies of 18F-GP1, a
new tracer for detection of
thrombi [23]
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indicated, showed an average fourfold reduction in effective
dose from 14 to 3.5 mSv using CZT SPECT. In a low-risk
subgroup with normal stress without a rest study, this was
reduced to as low as 2 mSv on average. Despite this dose
reduction, they showed in a subgroup of 159 patients using
coronarography as the gold standard that sensitivity was
retained, implying no loss in diagnostic efficacy.
This congress has shown that in cardiology, wemay be able
to provide faster and better answers with lower doses and
improved technology and with tools to quantify coronary
blood flow and reserve, or detect and assess prognosis in spe-
cific disorders such as amyloidosis, sarcoidosis, endocarditis
and heart failure. We quote Prof. Ignasi Carrio (from the mov-
ie shown during the Lecture): BOther new important develop-
ments will be PET tracers for the atherosclerotic plaque and
eventually also to image the vulnerable ones^.
Brain imaging: BChase that dream, together^
In neurodegeneration, enormous strides forward have been
made over the past decade, with disease-specific biomarkers,
such as amyloid, that have reached the clinic. In addition,
several targets have been investigated that go beyond the clas-
sical neurotransmitter systems.
Parkinson’s disease (PD) is not only amovement disorder, but
is also characterized by extramotor cerebral abnormalities and
extracranial symptoms caused by, for example, parasympathetic
denervation inducing vagal nerve pathology. In this year’s Marie
Curie Award-winning contribution, Borghammer et al. [30] from
Aarhus, Denmark, showed that extracerebral parasympathetic
pathology can be visualized using 11C-donepezil, which binds
to acetylcholinesterase and can be seen as amarker of cholinergic
innervation. A strong decrease in the small intestine and pancreas
was found in 12 PD patients and with almost only half of the
SUV compared to 12 matched healthy controls (Fig. 19). This
study is the first showing assessment of peripheral parasympa-
thetic disease involvement in PD.
Fazio et al. [31] reported on a highly specific 18F-labelled
dopamine transporter (DAT) ligand, PE2I, that has favourable
specificity over other transporters, as well as faster kinetics
and modelling properties than existing DAT ligands. While
up to 70 % loss in patients with early PD occurs in the puta-
men, high-resolution PET showed that the DAT signal in the
substantia nigra (SN) can be quantified, but with much lower
abnormality, indicating that the integrity of the SN cell bodies
is relatively preserved and that in PD mainly the terminals are
affected in the early disease course.
Several important modulatory or downstream targets that
affect dopaminergic neurotransmission are now under study
using molecular imaging. Several tracers targeting phospho-
diesterases (PDE), intracellular second messenger systems,
were presented at this symposium, including PDE2, PDE4
and PDE10A subtypes which all have high cerebral expres-
sion. Fazio et al. [32] used 18F-MNI-659, a PDE10A ligand,
showing very large changes in patients with early
Huntington’s disease (HD) even after partial volume correc-
tion. The effect was much larger compared with an only mod-
est D2 receptor change which was previously known as the
first abnormal imaging marker for HD (Fig. 20). Studies in
Fig. 18 Fractional uptake
determination in several forms of
cardiac amyloidosis using Carima
software [27]. TTR transthyretin,
FUR fractional uptake ratio, AL
amyloid load
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presymptomatic HD are being conducted to investigate
whether this biomarker may allow disease onset prediction
or to provide mechanistic proof for a possible therapeutic
target.
The glutamatergic system is another major neurotransmit-
ter system that has not received attention due to lack of appro-
priate radioligands, but is crucial in many disorders with
excitotoxicity (including neurodegeneration, epilepsy, addic-
tion, and schizophrenia). Salabert et al. [33] explored the pre-
clinical validation of 18F-FNM, a novel PET tracer for the N-
methyl-D-aspartate (NMDA) receptor, which is abundantly
expressed in cortical and subcortical grey matter. With good
blood–brain barrier crossing, fast pharmacokinetics and spe-
cific target validation shown by blocking studies, further
in vivo human studies with this promising compound are
awaited.
Onoe et al. [34] used PET imaging in conscious rhesus
monkeys in pharmacological experiments to elucidate a pos-
sible antidepressant mechanism of ketamine involving seroto-
nin 1B receptors. Ketamine upregulated the 5HT1B receptor
as measured by the novel ligand 11C-AZ10419369, only in
areas central in the circuitry involved in mood regulation,
the accumbens and ventral pallidum. Günther et al. [35] in-
vestigated neuroinflammation in rats with highly localized
Fig. 19 11C-Donepezil
acetylcholinesterase activity
determination in the small
intestine in Parkinson’s disease
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unilateral labyrinthectomy using 18F-GE180, a novel TSPO
ligand. The authors were able to follow the in vivo time course
of the inflammation associated with the initial vestibular syn-
drome over 30 days that decreased with vestibular compensa-
tion. They showed a remarkably strong in vivo signal in the
vestibular nuclei that was validated using autoradiography.
Simultaneous PET/MRI sparks high hopes for new re-
search applications in CNS imaging, and this area may also
contain the lowest-hanging fruit to allow implementation on a
more clinical routine basis. Barthel et al. [36] shared their first
experiences with combined amyloid PET/MRI imaging in
100 patients with mild cognitive impairment (MCI) or
Alzheimer‘s (AD), and showed that the combination of amy-
loid and structural imaging of the mesial temporal lobe (as a
marker of neuronal injury) significantly improves differential
diagnosis and clearly aids the early diagnosis of MCI
(Fig. 21).
Pooled post-mortem validation of amyloid imaging shows
high sensitivity and good specificity (98 % and 89 %, a neg-
ative predictive value of 96 %), confirming that amyloid im-
aging can reliably exclude amyloid pathology [37]. Maya
et al. [38] investigated 123I-ABC577 for measuring beta amy-
loid, and demonstrated good discrimination capacity between
AD patients and healthy controls in a pilot study, with the
advantage of low nonspecific white matter binding, thus po-
tentially expanding the clinical utility of amyloid imaging
using SPECT.
However, the field is also moving ‘beyond amyloid’.
Imaging trials have shown amyloid to be a very sensitive but
very early marker in the disease course of AD, which hampers
prediction of disease onset. As tau accumulation probably
occurs later in the course of AD in most patients, tau imaging
may provide a timelier marker of conversion to overt AD.
Moreover, it has potential to characterize the signature of other
neurodegenerative disorders that are purely tau-based, such as
frontal lobe dementia and progressive supranuclear palsy.
Devous et al. [39] provided test–retest data of 18F-AV1451
(formerly known as T807) that showed very good reproduc-
ibility of 4 – 5 % and high interreader consistency, both ad-
vantages necessary for picking up small changes in the early
course of the disease and for accurate quantitative evaluation
of disease-modifying therapies. Okamura et al. [40] shared the
first results in humans from a second-generation tau ligand,
18F-THK5351, which has a better signal-to-noise ratio and
less white matter uptake than previous Tohuku ligands
(Fig. 22).
In general, presentations at the congress on CNS imaging
were devoted to developments in tracers, methodology and
disease applications. Despite progress in the field of neurode-
generation, there seems to be a worrying decline in contribu-
tions in psychiatry. This may in part be reflected by less in-
vestment by the pharmaceutical industry in novel targets,
since about two-thirds of new radioligands originate in or
from collaboration with industry. As molecular imaging re-
mains a unique bridge between genetics and human behav-
iour, new and collaborative efforts in this exciting area should
be stimulated. This was also stressed by Prof. Gitte Moos-
Knudsen, whom we quote (from the movie shown during
the Lecture): BThe main challenges for CNS imaging are the
declining number of active programs in pharmaceutical
Fig. 21 Simultaneous T1-
weighted and 18F-florbetaben
amyloid PET/MRI in MCI
patients, allowing improved
differential diagnosis and
prognosis assessment in a one-
stop-shop fashion [36]
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companies resulting in fewer compounds and targets, the cost
of PET imaging creating a tendency of underpowered studies,
and the need for more and better collaborations not only be-
tween imaging centres, but also with basic scientists.^
Oncology and radionuclide therapy: BMaking molecular
imaging a clinical reality^
Oncology remains the most important category of abstracts on
both diagnostic and therapeutic applications. Many abstracts
describing clinical studies on new radiopharmaceuticals were
among the highest rated and were therefore selected for inclu-
sion in the Highlights Lecture.
Bodet-Milin et al. [41] earlier showed the feasibility of
pretargeting using anti-CEA bispecific mAb and radiolabelled
hapten peptides. They now compared the sensitivity of whole-
body pretargeted immuno-PET/CTand 18F-DOPA PET/CT in
metastatic patients with medullary thyroid carcinoma (MTC)
and demonstrated the potential of anti-CEA pretargeted
immuno-PET/CT for staging MTC patients, especially for
nodes, liver, and bone evaluation. Pretargeted immuno-PET
showed a higher overall sensitivity than CT and 18F-DOPA
PET/CT, whereas CT seemed to be more effective than
immuno-PET/CT for detecting lung metastases. MRI showed
better sensitivity than immuno-PET/CT for bone examination,
but immuno-PET/CT allowed detection of bone lesions in
areas not explored by MRI (Fig. 23).
In the next study, the same group [42] aimed at optimizing
molar doses and pretargeting intervals of bispecific mAb and
hapten peptide. High tumour uptake and tumour-to-
mediastinum blood pool ratios were obtained with pretargeted
anti-CEA immuno-PET, especially when using optimized
pretargeting parameters: bispecific mAb/peptide molar ratio
of 40 and a pretargeting delay of 30 h.
Another target of interest is HER2, a transmembrane tyro-
sine kinase receptor overexpressed in 12 – 25 % of breast
cancers. Imaging of HER2 enables noninvasive repetitive
Fig. 22 18F-THK-5351, a novel
radiotracer for PET tau imaging
with improved signal-to-noise
ratio and lower white matter
uptake [40]
Fig. 23 Pretargeted immuno-
PET versus CT, MRI and 18F-
DOPA-PET [42]
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determination of HER2 status and stratification of patients for
HER2-targeted therapy. Sörensen et al. [43] performed a
phase I clinical trial of the HER2-binding peptide molecule
ABY025 labelled with 68Ga for PET to investigate the safety,
biodistribution, pharmacokinetics, effect of two peptide
masses, and correlation of uptake in tumours with immuno-
histochemistry. 68Ga-ABY025 PET/CT was performed with-
out safety issues and appeared to be a most promising tool for
assessing whole-body HER2 receptor status in metastatic
breast cancer and imaging with the higher peptide dose
(500 μg) at 2 h after injection appeared the best combination
for routine use (Fig. 24)
GLP-1-labelled analogues are considered useful tools for
visualization of different tumours. Sowa-Staszczak et al. [44]
studied the diagnostic efficiency of [Lys40(Ahx-
HYNIC-99mTc/EDDA)NH2]-exendin-4 scintigraphy. The au-
thors concluded that 99mTc-GLP-1 receptor scintigraphy is a
very useful diagnostic tool in patients with clinical symptoms
of insulinoma. It enabled the localization of even very small
tumours with excellent sensitivity. Moreover, 99mTc-GLP-1
receptor imaging could also be useful in patients with MTC,
phaeochromocytoma and gastrinoma, especially when other
diagnostic methods are equivocal.
Currently there is huge interest (and also during this meet-
ing) in prostate cancer imaging. KleinJan et al. [45] presented
a hybrid tracer, indocyanine green (ICG) 99mTc-nanocolloid,
that was earlier found to successfully complement intraopera-
tive radioguidance towards the sentinel node(s) with optical
fluorescence identification. For sophisticated procedures such
as laparoscopic robot-assisted radical prostatectomy com-
bined with sentinel node biopsy, fluorescence-based identifi-
cation however required further optimization. They evaluated
the effect of tracer preparation, injection technique, and the
fluorescence imaging hardware on intraoperative sentinel
node identification rate and found a significant improvement
in intraoperative fluorescence-assisted sentinel node identifi-
cation after stepwise optimization of tracer formulation and
the fluorescence laparoscope, while preoperative SPECT/CT
remained an essential tool for locating the sentinel nodes.
Prostate cancer cells express different interesting targets for
imaging and therapy probes on their membranes. Today's clin-
ical imaging modalities commonly applied to the evaluation
of patients with prostate cancer include bone scan, CT and
MRI. However, due to the biochemical nature of the disease
and its clinical and anatomical course, current imaging tech-
niques have considerable limitations in accurately defining the
presence and extent of disease. PSMA is a most promising
target for imaging and therapy, and in this area several excel-
lent papers were presented. PSMA is upregulated in aggres-
sive cancers and metastases. Vallabhajosula et al. [46] per-
formed a study using 99mTc-MIP-1404, a small molecule
showing specific binding to PSMA (Fig. 25). Compared to
bone scan, MRI and CT, PSMA imaging with 99mTc-MIP-
1404 detected primary and metastatic prostate cancer in this
study with higher specificity. Uptake in the prostate gland
lesions correlated well with both Gleason score and PSMA
expression. This pilot study clearly documented that PSMA
scanning with 99mTc-MIP-1404 may be an appropriate
Fig. 24 68Ga-ABY025 PET/CT
imaging in metastatic breast
cancer [43]
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imaging biomarker for early detection of prostate cancer and
for selecting patients for therapy.
Kulkarni et al. [47] analysed a new PET tracer for PSMA
imaging (68Ga-PSMA-HBED-CC). The aim of their study
was to investigate the role of 68Ga-PSMA-HBED-CC PET/
CT in patients presenting with rising PSA levels. The high
target-to-background ratio enabled accurate detection of very
small lesions and of early bone marrow metastases. The au-
thors concluded that 68Ga-PSMA-HBED-CC is a very sensi-
tive and specific PET tracer for the detection of prostate cancer
with residual/recurrent disease and its metastases. 68Ga-
PSMA-HBED-CC PET/CT may also be useful for effective
Fig. 25 Prostate cancer imaging
using 99mTc-MIP-1404 [46]
Fig. 26 Antitumour efficacy of
177Lu-PSMA-TUM1 [48]
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stratification of patients undergoing radioligand therapy with
177Lu-labelled PSMA ligands. This theranostic approach was
also studied by the same authors [48] using EuK-Sub-KFF-
DOTAGA (PSMA-TUM1), a promising PSMA-targeting li-
gand exhibiting high and specific uptake in prostate cancer.
The aim of the study was to determine the safety and efficacy
of 177Lu-PSMA-TUM1 in an initial cohort of patients with
castrate-resistant prostate cancer. The treatment was well tol-
erated by all patients without any significant adverse effects or
alterations in any of the laboratory parameters or renal func-
tion. The initial results demonstrated that radionuclide therapy
with 177Lu-PSMA-TUM1 is both safe and effective in
castrate-resistant metastatic prostate cancer with appropriate
selection and follow-up of patients by 68Ga-PSMA-HBED-
CC PET/CT (Fig. 26), making PSMA an excellent target for
both diagnostic imaging and radiotherapeutic approaches.
Another radionuclide therapy study using a novel tracer
was presented by Królicki et al. [49], who investigated a novel
treatment strategy for glioblastoma multiforme that is charac-
terized by a very bad prognosis with an overall survival of
9 – 15 months. Substance P, a ligand for the NK-1 receptor
system extensively expressed in glioma cells, was labelled
with the α emitter 213Bi, offering high potential for selective
irradiation of tumours while minimizing damage to adjacent
tissue. Treatment of patients suffering from recurrent disease
with 213Bi-substance P appeared safe and was well tolerated.
Follow-up of therapeutic responses and toxicity was still on
going at the time of the meeting; the median survival of the
patients with glioblastoma multiforme was >30 months from
initial diagnosis. The authors concluded that targeted α thera-
py with 213Bi-substance P is a promising novel option for
treatment of recurrent glioblastoma multiforme.
At this meeting the most promising tracers currently being
investigated for clinical imaging and therapeutic applications
were discussed. To translate these successes into clinical real-
ity, Bwe now need to work on efficient and harmonized trial
design for validation and dissemination of novel agents and
get new radiopharmaceuticals FDA/EMA approved and reim-
bursed for clinical use^ (quote Prof.WolfgangWeber from the
movie shown during the Lecture).
Conclusion
Nuclear medicine has benefited from rapid technological evo-
lution that has yielded new imaging possibilities, new hard-
ware and software developments and new radiopharmaceuti-
cals which have gained widespread acceptance. The combina-
tion of diagnostic imaging, tissue characterization, function
measurement and targeted therapy in nuclear medicine re-
mains very powerful. The EANM 2014 Congress provided a
sample of such novel nuclear medicine contributions with
excellent innovations in (pre)clinical imaging methodology,
physics, radiopharmaceuticals and radiochemistry. Novel ra-
dionuclide applications in both diagnosis and therapy were
presented. Significant progress was demonstrated in the clin-
ical applications of existing nuclear medicine procedures,
whereas new applications are under development in preclini-
cal and early clinical stages.
We believe that the achievements of the Gothenburg
EANM Congress are symbolized by the renowned interna-
tional success of the group ABBA, who won the European
Song Contest in 1974, and who’s member Björn (Ulvaeus)
was born in Gothenburg. The BSuper Trouper^ nuclear med-
icine studies presented at the congress, spanning multiple ap-
plication domains, demonstrated again the crucial role that
nuclear medicine can play in contemporary medicine and bio-
medical science.
Novel radiopharmaceutical applications in both diagnosis
and therapy were presented, the time to make the transition to
a lasting clinical reality is now!We should collaborate to pave
the translational road, to bring promising novel tracers to
(multicentre) clinical studies and reduce current hurdles, in-
cluding legislation, high costs and reimbursement issues. BI
Have a Dream, a Song to Sing^: we call upon all collaborators
in nuclear medicine to join forces, to reduce internal compe-
tition, and to work on harmonized protocols in order to make
promising new developments a clinical success both in diag-
nostics and therapy.
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